The 3p21.31 genetic locus promotes progression to type 1 diabetes through the CCR2/CCL2 pathway
Multiple cross-sectional and longitudinal studies have shown that serum levels of the chemokine ligand 2 (CCL-2) are associated with type 1 diabetes (T1D), although the direction of effect differs. We assessed CCL-2 serum levels in a longitudinal cohort to clarify this association, combined with gen...
Saved in:
| Published in | Journal of translational autoimmunity (Online) Vol. 4; p. 100127 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier B.V
01.01.2021
Elsevier |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2589-9090 2589-9090 |
| DOI | 10.1016/j.jtauto.2021.100127 |
Cover
Loading…
| Abstract | Multiple cross-sectional and longitudinal studies have shown that serum levels of the chemokine ligand 2 (CCL-2) are associated with type 1 diabetes (T1D), although the direction of effect differs. We assessed CCL-2 serum levels in a longitudinal cohort to clarify this association, combined with genetic data to elucidate the regulatory role of CCL-2 in T1D pathogenesis.
The Diabetes Autoimmunity Study in the Young (DAISY) followed 310 subjects with high risk of developing T1D. Of these, 42 became persistently seropositive for islet autoantibodies but did not develop T1D (non-progressors); 48 did develop T1D (progressors). CCL-2 serum levels among the three study groups were compared using linear mixed models adjusting for age, sex, HLA genotype, and family history of T1D. Summary statistics were obtained from the CCL-2 protein quantitative trait loci (pQTL) and CCR2 expression QTL (eQTL) studies. The T1D fine mapping association data were provided by the Type 1 Diabetes Genetics Consortium (T1DGC).
Serum CCL-2 levels were significantly lower in both progressors (p = 0.004) and non-progressors (p = 0.005), compared to controls. Two SNPs (rs1799988 and rs746492) in the 3p21.31 genetic locus, which includes the CCL-2 receptor, CCR2, were associated with increased CCR2 expression (p = 8.2e-5 and 5.2e-5, respectively), decreased CCL-2 serum level (p = 2.41e-9 and 6.21e-9, respectively), and increased risk of T1D (p = 7.9e-5 and 7.9e-5, respectively).
The 3p21.31 genetic region is associated with developing T1D through regulatory control of the CCR2/CCL2 immune pathway.
•Serum CCL-2 levels are lower in individuals with islet autoantibodies and type 1 diabetes compared to controls.•Serum CCL-2 levels are associated with the 3p21.31 genetic locus.•The 3p21.31 genetic locus is associated with type 1 diabetes.•The 3p21.31 genetic locus is associated with gene expression of the CCL-2 receptor, CCR2. |
|---|---|
| AbstractList | Multiple cross-sectional and longitudinal studies have shown that serum levels of the chemokine ligand 2 (CCL-2) are associated with type 1 diabetes (T1D), although the direction of effect differs. We assessed CCL-2 serum levels in a longitudinal cohort to clarify this association, combined with genetic data to elucidate the regulatory role of CCL-2 in T1D pathogenesis.The Diabetes Autoimmunity Study in the Young (DAISY) followed 310 subjects with high risk of developing T1D. Of these, 42 became persistently seropositive for islet autoantibodies but did not develop T1D (non-progressors); 48 did develop T1D (progressors). CCL-2 serum levels among the three study groups were compared using linear mixed models adjusting for age, sex, HLA genotype, and family history of T1D. Summary statistics were obtained from the CCL-2 protein quantitative trait loci (pQTL) and CCR2 expression QTL (eQTL) studies. The T1D fine mapping association data were provided by the Type 1 Diabetes Genetics Consortium (T1DGC).Serum CCL-2 levels were significantly lower in both progressors (p = 0.004) and non-progressors (p = 0.005), compared to controls. Two SNPs (rs1799988 and rs746492) in the 3p21.31 genetic locus, which includes the CCL-2 receptor, CCR2, were associated with increased CCR2 expression (p = 8.2e-5 and 5.2e-5, respectively), decreased CCL-2 serum level (p = 2.41e-9 and 6.21e-9, respectively), and increased risk of T1D (p = 7.9e-5 and 7.9e-5, respectively).The 3p21.31 genetic region is associated with developing T1D through regulatory control of the CCR2/CCL2 immune pathway. Multiple cross-sectional and longitudinal studies have shown that serum levels of the chemokine ligand 2 (CCL-2) are associated with type 1 diabetes (T1D), although the direction of effect differs. We assessed CCL-2 serum levels in a longitudinal cohort to clarify this association, combined with genetic data to elucidate the regulatory role of CCL-2 in T1D pathogenesis. The Diabetes Autoimmunity Study in the Young (DAISY) followed 310 subjects with high risk of developing T1D. Of these, 42 became persistently seropositive for islet autoantibodies but did not develop T1D (non-progressors); 48 did develop T1D (progressors). CCL-2 serum levels among the three study groups were compared using linear mixed models adjusting for age, sex, HLA genotype, and family history of T1D. Summary statistics were obtained from the CCL-2 protein quantitative trait loci (pQTL) and CCR2 expression QTL (eQTL) studies. The T1D fine mapping association data were provided by the Type 1 Diabetes Genetics Consortium (T1DGC). Serum CCL-2 levels were significantly lower in both progressors (p = 0.004) and non-progressors (p = 0.005), compared to controls. Two SNPs (rs1799988 and rs746492) in the 3p21.31 genetic locus, which includes the CCL-2 receptor, CCR2 , were associated with increased CCR2 expression (p = 8.2e-5 and 5.2e-5, respectively), decreased CCL-2 serum level (p = 2.41e-9 and 6.21e-9, respectively), and increased risk of T1D (p = 7.9e-5 and 7.9e-5, respectively). The 3p21.31 genetic region is associated with developing T1D through regulatory control of the CCR2/CCL2 immune pathway. • Serum CCL-2 levels are lower in individuals with islet autoantibodies and type 1 diabetes compared to controls. • Serum CCL-2 levels are associated with the 3p21.31 genetic locus. • The 3p21.31 genetic locus is associated with type 1 diabetes. • The 3p21.31 genetic locus is associated with gene expression of the CCL-2 receptor, CCR2 . Multiple cross-sectional and longitudinal studies have shown that serum levels of the chemokine ligand 2 (CCL-2) are associated with type 1 diabetes (T1D), although the direction of effect differs. We assessed CCL-2 serum levels in a longitudinal cohort to clarify this association, combined with genetic data to elucidate the regulatory role of CCL-2 in T1D pathogenesis. The Diabetes Autoimmunity Study in the Young (DAISY) followed 310 subjects with high risk of developing T1D. Of these, 42 became persistently seropositive for islet autoantibodies but did not develop T1D (non-progressors); 48 did develop T1D (progressors). CCL-2 serum levels among the three study groups were compared using linear mixed models adjusting for age, sex, HLA genotype, and family history of T1D. Summary statistics were obtained from the CCL-2 protein quantitative trait loci (pQTL) and expression QTL (eQTL) studies. The T1D fine mapping association data were provided by the Type 1 Diabetes Genetics Consortium (T1DGC). Serum CCL-2 levels were significantly lower in both progressors (p = 0.004) and non-progressors (p = 0.005), compared to controls. Two SNPs (rs1799988 and rs746492) in the 3p21.31 genetic locus, which includes the CCL-2 receptor, , were associated with increased expression (p = 8.2e-5 and 5.2e-5, respectively), decreased CCL-2 serum level (p = 2.41e-9 and 6.21e-9, respectively), and increased risk of T1D (p = 7.9e-5 and 7.9e-5, respectively). The 3p21.31 genetic region is associated with developing T1D through regulatory control of the CCR2/CCL2 immune pathway. Multiple cross-sectional and longitudinal studies have shown that serum levels of the chemokine ligand 2 (CCL-2) are associated with type 1 diabetes (T1D), although the direction of effect differs. We assessed CCL-2 serum levels in a longitudinal cohort to clarify this association, combined with genetic data to elucidate the regulatory role of CCL-2 in T1D pathogenesis. The Diabetes Autoimmunity Study in the Young (DAISY) followed 310 subjects with high risk of developing T1D. Of these, 42 became persistently seropositive for islet autoantibodies but did not develop T1D (non-progressors); 48 did develop T1D (progressors). CCL-2 serum levels among the three study groups were compared using linear mixed models adjusting for age, sex, HLA genotype, and family history of T1D. Summary statistics were obtained from the CCL-2 protein quantitative trait loci (pQTL) and CCR2 expression QTL (eQTL) studies. The T1D fine mapping association data were provided by the Type 1 Diabetes Genetics Consortium (T1DGC). Serum CCL-2 levels were significantly lower in both progressors (p = 0.004) and non-progressors (p = 0.005), compared to controls. Two SNPs (rs1799988 and rs746492) in the 3p21.31 genetic locus, which includes the CCL-2 receptor, CCR2, were associated with increased CCR2 expression (p = 8.2e-5 and 5.2e-5, respectively), decreased CCL-2 serum level (p = 2.41e-9 and 6.21e-9, respectively), and increased risk of T1D (p = 7.9e-5 and 7.9e-5, respectively). The 3p21.31 genetic region is associated with developing T1D through regulatory control of the CCR2/CCL2 immune pathway.Multiple cross-sectional and longitudinal studies have shown that serum levels of the chemokine ligand 2 (CCL-2) are associated with type 1 diabetes (T1D), although the direction of effect differs. We assessed CCL-2 serum levels in a longitudinal cohort to clarify this association, combined with genetic data to elucidate the regulatory role of CCL-2 in T1D pathogenesis. The Diabetes Autoimmunity Study in the Young (DAISY) followed 310 subjects with high risk of developing T1D. Of these, 42 became persistently seropositive for islet autoantibodies but did not develop T1D (non-progressors); 48 did develop T1D (progressors). CCL-2 serum levels among the three study groups were compared using linear mixed models adjusting for age, sex, HLA genotype, and family history of T1D. Summary statistics were obtained from the CCL-2 protein quantitative trait loci (pQTL) and CCR2 expression QTL (eQTL) studies. The T1D fine mapping association data were provided by the Type 1 Diabetes Genetics Consortium (T1DGC). Serum CCL-2 levels were significantly lower in both progressors (p = 0.004) and non-progressors (p = 0.005), compared to controls. Two SNPs (rs1799988 and rs746492) in the 3p21.31 genetic locus, which includes the CCL-2 receptor, CCR2, were associated with increased CCR2 expression (p = 8.2e-5 and 5.2e-5, respectively), decreased CCL-2 serum level (p = 2.41e-9 and 6.21e-9, respectively), and increased risk of T1D (p = 7.9e-5 and 7.9e-5, respectively). The 3p21.31 genetic region is associated with developing T1D through regulatory control of the CCR2/CCL2 immune pathway. Multiple cross-sectional and longitudinal studies have shown that serum levels of the chemokine ligand 2 (CCL-2) are associated with type 1 diabetes (T1D), although the direction of effect differs. We assessed CCL-2 serum levels in a longitudinal cohort to clarify this association, combined with genetic data to elucidate the regulatory role of CCL-2 in T1D pathogenesis. The Diabetes Autoimmunity Study in the Young (DAISY) followed 310 subjects with high risk of developing T1D. Of these, 42 became persistently seropositive for islet autoantibodies but did not develop T1D (non-progressors); 48 did develop T1D (progressors). CCL-2 serum levels among the three study groups were compared using linear mixed models adjusting for age, sex, HLA genotype, and family history of T1D. Summary statistics were obtained from the CCL-2 protein quantitative trait loci (pQTL) and CCR2 expression QTL (eQTL) studies. The T1D fine mapping association data were provided by the Type 1 Diabetes Genetics Consortium (T1DGC). Serum CCL-2 levels were significantly lower in both progressors (p = 0.004) and non-progressors (p = 0.005), compared to controls. Two SNPs (rs1799988 and rs746492) in the 3p21.31 genetic locus, which includes the CCL-2 receptor, CCR2, were associated with increased CCR2 expression (p = 8.2e-5 and 5.2e-5, respectively), decreased CCL-2 serum level (p = 2.41e-9 and 6.21e-9, respectively), and increased risk of T1D (p = 7.9e-5 and 7.9e-5, respectively). The 3p21.31 genetic region is associated with developing T1D through regulatory control of the CCR2/CCL2 immune pathway. •Serum CCL-2 levels are lower in individuals with islet autoantibodies and type 1 diabetes compared to controls.•Serum CCL-2 levels are associated with the 3p21.31 genetic locus.•The 3p21.31 genetic locus is associated with type 1 diabetes.•The 3p21.31 genetic locus is associated with gene expression of the CCL-2 receptor, CCR2. |
| ArticleNumber | 100127 |
| Author | Purohit, Sharad bin Satter, Khaled Waugh, Kathleen Rich, Stephen S. Tran, Paul MH Rewers, Marian Hopkins, Diane Dong, Fran Onengut-Gumuscu, Suna Kim, Eileen She, Jin-Xiong |
| Author_xml | – sequence: 1 givenname: Paul MH orcidid: 0000-0003-2197-4376 surname: Tran fullname: Tran, Paul MH organization: Center for Biotechnology and Genomic Medicine, Medical College of Georgia, 1120 15th Street, Augusta, GA, 30912, USA – sequence: 2 givenname: Sharad surname: Purohit fullname: Purohit, Sharad organization: Center for Biotechnology and Genomic Medicine, Medical College of Georgia, 1120 15th Street, Augusta, GA, 30912, USA – sequence: 3 givenname: Eileen orcidid: 0000-0002-6782-1810 surname: Kim fullname: Kim, Eileen organization: Center for Biotechnology and Genomic Medicine, Medical College of Georgia, 1120 15th Street, Augusta, GA, 30912, USA – sequence: 4 givenname: Khaled orcidid: 0000-0002-2344-3002 surname: bin Satter fullname: bin Satter, Khaled organization: Center for Biotechnology and Genomic Medicine, Medical College of Georgia, 1120 15th Street, Augusta, GA, 30912, USA – sequence: 5 givenname: Diane surname: Hopkins fullname: Hopkins, Diane organization: Center for Biotechnology and Genomic Medicine, Medical College of Georgia, 1120 15th Street, Augusta, GA, 30912, USA – sequence: 6 givenname: Kathleen surname: Waugh fullname: Waugh, Kathleen organization: Barbara Davis Center for Diabetes, University of Colorado Denver, Mail Stop A-140, 1775 Aurora Court, Aurora, CO, 80045, USA – sequence: 7 givenname: Fran surname: Dong fullname: Dong, Fran organization: Barbara Davis Center for Diabetes, University of Colorado Denver, Mail Stop A-140, 1775 Aurora Court, Aurora, CO, 80045, USA – sequence: 8 givenname: Suna orcidid: 0000-0002-6563-8334 surname: Onengut-Gumuscu fullname: Onengut-Gumuscu, Suna organization: Center for Public Health Genomics, University of Virginia School of Medicine, Charlottesville, VA, USA – sequence: 9 givenname: Stephen S. orcidid: 0000-0003-3872-7793 surname: Rich fullname: Rich, Stephen S. organization: Center for Public Health Genomics, University of Virginia School of Medicine, Charlottesville, VA, USA – sequence: 10 givenname: Marian orcidid: 0000-0003-3829-9207 surname: Rewers fullname: Rewers, Marian organization: Barbara Davis Center for Diabetes, University of Colorado Denver, Mail Stop A-140, 1775 Aurora Court, Aurora, CO, 80045, USA – sequence: 11 givenname: Jin-Xiong surname: She fullname: She, Jin-Xiong email: jshe@mail.mcg.edu organization: Center for Biotechnology and Genomic Medicine, Medical College of Georgia, 1120 15th Street, Augusta, GA, 30912, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35005592$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkk1r3DAQhk1JadI0_6AUH3vZjUa2bLmHQjH9CCwUSnoWsjS2ZbyWK8kJ---rjTcl6aE9zaCZeV40875OziY7YZK8BbIFAsX1sB2CXILdUkIhPhGg5YvkgjJebSpSkbMn-Xly5f1ACKEMAAr6KjnPGCGMVfQiEbc9ptkcIRmkHU4YjEpHqxafzs7ubcCHpHPovbFTGmwaDjOmkGojGzyWQ-_s0vUxYlrXP-h1Xe9oOsvQ38vDm-RlK0ePV6d4mfz88vm2_rbZff96U3_abRSjVdgw1rCshLIhpISMY6VlBUVbkIwXeSU11wyzUvGSta3kTDeSKqV1rjhXukSWXSY3K1dbOYjZmb10B2GlEQ8P1nVCuvi3EQUwqLI8p5TpKm8ka2SUUDojpGlyyCGyPq6seWn2qBVOwcnxGfR5ZTK96Oyd4CUUBaMR8P4EcPbXgj6IvfEKx1FOaBcvaAGcQc5pEVvfPdX6I_J4odjwYW1QznrvsBXKBBniLaK0GQUQcXSEGMTqCHF0hFgdEYfzv4Yf-f8ZOy0A48XuDDrhlcFJoTYOVYgrNf8G_AZV89AH |
| CitedBy_id | crossref_primary_10_1007_s10528_024_10669_w crossref_primary_10_1038_s41598_024_65732_8 |
| Cites_doi | 10.1007/s001250050514 10.1093/nar/gky1120 10.4049/jimmunol.1601458 10.1016/S0140-6736(18)31320-5 10.1056/NEJM198605223142106 10.1086/519795 10.1210/JC.2015-1388 10.1200/JCO.2018.36.5_suppl.92 10.1038/s42255-020-00287-2 10.1073/pnas.1910856117 10.1172/JCI115950 10.3109/08916930903246464 10.1038/ng.381 10.1358/dnp.2010.23.4.1453629 10.1111/jnc.13881 10.1093/bioinformatics/btq419 10.1007/s12272-013-0161-z 10.1016/j.ekir.2018.07.010 10.1016/j.intimp.2020.106314 10.1038/ng.2653 10.1111/j.1399-5448.2011.00774.x 10.1016/j.amjcard.2010.11.005 10.1186/1476-9255-6-32 10.1001/jama.298.12.1420 10.1016/S0140-6736(12)60110-X 10.1038/nm.3933 10.2307/2529876 10.2337/diabetes.51.1.55 10.1002/art.23591 10.3390/microorganisms8071031 10.1371/journal.pone.0174840 10.1016/S0140-6736(11)61931-4 10.1515/jpem-2015-0340 10.1136/ard.2005.037176 10.1172/JCI24335 10.1101/gr.229102 10.1038/ng.3245 10.1186/s13073-020-00754-1 10.1034/j.1600-0404.2001.104002088.x 10.1056/NEJMoa1902226 10.1186/1742-2094-11-23 10.1001/jama.2014.16425 10.1016/j.cyto.2012.06.018 10.4049/jimmunol.1900961 10.1016/S0140-6736(19)32127-0 10.1038/s41598-017-00513-0 10.1007/s00109-005-0637-5 10.1016/S0952-7915(01)00277-1 |
| ContentType | Journal Article |
| Copyright | 2021 The Authors 2021 The Authors. 2021 The Authors 2021 |
| Copyright_xml | – notice: 2021 The Authors – notice: 2021 The Authors. – notice: 2021 The Authors 2021 |
| DBID | 6I. AAFTH AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.1016/j.jtauto.2021.100127 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2589-9090 |
| ExternalDocumentID | oai_doaj_org_article_1519344225d94ba5ba649cd300bb4141 PMC8716652 35005592 10_1016_j_jtauto_2021_100127 S2589909021000472 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: NICHD NIH HHS grantid: R21 HD050196 – fundername: NIDDK NIH HHS grantid: U01 DK062418 – fundername: NIDDK NIH HHS grantid: R01 DK032493 – fundername: NICHD NIH HHS grantid: R01 HD037800 – fundername: NICHD NIH HHS grantid: R33 HD050196 – fundername: NIDDK NIH HHS grantid: F30 DK121461 – fundername: NIDDK NIH HHS grantid: P30 DK116073 |
| GroupedDBID | 0SF 53G 6I. AAEDW AAFTH AALRI AAXUO ACLIJ AEXQZ AITUG ALMA_UNASSIGNED_HOLDINGS AMRAJ EBS EJD FDB GROUPED_DOAJ M41 M~E NCXOZ OK1 ROL RPM 0R~ AAYWO AAYXX ACVFH ADCNI ADVLN AEUPX AFJKZ AFPUW AIGII AKBMS AKYEP APXCP CITATION NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c529t-55b53717b007138e9da916f6038649ad8d5e37c875ffa85dba2ccdd4c88cd7e53 |
| IEDL.DBID | DOA |
| ISSN | 2589-9090 |
| IngestDate | Wed Aug 27 01:25:59 EDT 2025 Thu Aug 21 18:45:42 EDT 2025 Fri Jul 11 11:04:15 EDT 2025 Mon Jul 21 06:06:12 EDT 2025 Tue Jul 01 03:50:17 EDT 2025 Thu Apr 24 22:56:45 EDT 2025 Tue Jul 25 21:00:10 EDT 2023 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | MCP1 T1D Fine mapping CCL2 Autoimmune DAISY CCR2 |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. 2021 The Authors. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c529t-55b53717b007138e9da916f6038649ad8d5e37c875ffa85dba2ccdd4c88cd7e53 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this work. |
| ORCID | 0000-0003-3872-7793 0000-0003-3829-9207 0000-0003-2197-4376 0000-0002-2344-3002 0000-0002-6782-1810 0000-0002-6563-8334 |
| OpenAccessLink | https://doaj.org/article/1519344225d94ba5ba649cd300bb4141 |
| PMID | 35005592 |
| PQID | 2618514826 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_1519344225d94ba5ba649cd300bb4141 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8716652 proquest_miscellaneous_2618514826 pubmed_primary_35005592 crossref_citationtrail_10_1016_j_jtauto_2021_100127 crossref_primary_10_1016_j_jtauto_2021_100127 elsevier_sciencedirect_doi_10_1016_j_jtauto_2021_100127 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-01-01 |
| PublicationDateYYYYMMDD | 2021-01-01 |
| PublicationDate_xml | – month: 01 year: 2021 text: 2021-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Journal of translational autoimmunity (Online) |
| PublicationTitleAlternate | J Transl Autoimmun |
| PublicationYear | 2021 |
| Publisher | Elsevier B.V Elsevier |
| Publisher_xml | – name: Elsevier B.V – name: Elsevier |
| References | Livingstone (bib3) 2015; 313 Flores-Toro (bib47) 2020; 117 Vergunst (bib26) 2008; 58 Poma (bib44) 2020; 8 Lonsdale (bib46) 2013; 45 Grieb, Merk, Bernhagen, Bucala (bib15) 2010; 23 Rewers (bib32) 1996; 39 Zhao (bib30) 2019; 203 Gale (bib49) 2018; 3 Dayan, Korah, Tatovic, Bundy, Herold (bib52) 2019; 394 Koch (bib21) 1992; 90 Weisberg (bib38) 2006; 116 Haringman, Smeets, Reinders-Blankert, Tak (bib22) 2006; 65 Solomon, Balasa, Sarvetnick (bib13) 2010; 43 Ismail (bib16) 2016; 29 Li (bib7) 2015; 21 Quinones (bib20) 2005; 83 Pruim (bib37) 2010; 26 Hillary (bib40) 2020; 12 Vergunst (bib50) 2008; 58 Eisenbarth (bib1) 1986; 314 Onengut-Gumuscu (bib6) 2015; 47 Bose, Cho (bib23) 2013; 36 Novakova (bib24) 2017; 141 Cui, Chu, Chen (bib27) 2020; 83 Herold (bib4) 2019; 381 Godessart, Kunkel (bib8) 2001; 13 Draper, Smith (bib34) 1998 Cortes, Brown (bib45) 2011; 13 Gilbert (bib28) 2011; 107 Hagopian (bib43) 2011; 12 Laird, Ware (bib35) 1982; 38 Buniello (bib39) 2019; 47 Linehan (bib48) 2018; 36 Wang (bib29) 2009; 6 Folkersen (bib31) 2020; 2 Waugh (bib17) 2017; 12 Swerdlow (bib42) 2012; 379 Vogel (bib11) 2014; 11 Norris (bib33) 2007; 298 Purcell (bib36) 2007; 81 Bakos (bib10) 2017; 198 Sindern (bib25) 2001; 104 Piemonti (bib19) 2002; 51 Sarwar (bib41) 2012; 379 Purohit (bib14) 2015; 100 Gilbert (bib51) 2011; 107 DiMeglio, Evans-Molina, Oram (bib2) 2018; 391 Kent (bib9) 2002; 12 Barrett (bib5) 2009; 41 Chen (bib12) 2017; 7 Panee (bib18) 2012; 60 Buniello (10.1016/j.jtauto.2021.100127_bib39) 2019; 47 Barrett (10.1016/j.jtauto.2021.100127_bib5) 2009; 41 Wang (10.1016/j.jtauto.2021.100127_bib29) 2009; 6 Hillary (10.1016/j.jtauto.2021.100127_bib40) 2020; 12 Rewers (10.1016/j.jtauto.2021.100127_bib32) 1996; 39 Gilbert (10.1016/j.jtauto.2021.100127_bib51) 2011; 107 Herold (10.1016/j.jtauto.2021.100127_bib4) 2019; 381 Sindern (10.1016/j.jtauto.2021.100127_bib25) 2001; 104 Gale (10.1016/j.jtauto.2021.100127_bib49) 2018; 3 Purcell (10.1016/j.jtauto.2021.100127_bib36) 2007; 81 Panee (10.1016/j.jtauto.2021.100127_bib18) 2012; 60 Draper (10.1016/j.jtauto.2021.100127_bib34) 1998 Waugh (10.1016/j.jtauto.2021.100127_bib17) 2017; 12 Quinones (10.1016/j.jtauto.2021.100127_bib20) 2005; 83 Weisberg (10.1016/j.jtauto.2021.100127_bib38) 2006; 116 Sarwar (10.1016/j.jtauto.2021.100127_bib41) 2012; 379 Linehan (10.1016/j.jtauto.2021.100127_bib48) 2018; 36 Flores-Toro (10.1016/j.jtauto.2021.100127_bib47) 2020; 117 Dayan (10.1016/j.jtauto.2021.100127_bib52) 2019; 394 Chen (10.1016/j.jtauto.2021.100127_bib12) 2017; 7 Cortes (10.1016/j.jtauto.2021.100127_bib45) 2011; 13 Haringman (10.1016/j.jtauto.2021.100127_bib22) 2006; 65 Koch (10.1016/j.jtauto.2021.100127_bib21) 1992; 90 Bakos (10.1016/j.jtauto.2021.100127_bib10) 2017; 198 Vogel (10.1016/j.jtauto.2021.100127_bib11) 2014; 11 Poma (10.1016/j.jtauto.2021.100127_bib44) 2020; 8 Kent (10.1016/j.jtauto.2021.100127_bib9) 2002; 12 Vergunst (10.1016/j.jtauto.2021.100127_bib26) 2008; 58 Laird (10.1016/j.jtauto.2021.100127_bib35) 1982; 38 Godessart (10.1016/j.jtauto.2021.100127_bib8) 2001; 13 Pruim (10.1016/j.jtauto.2021.100127_bib37) 2010; 26 Hagopian (10.1016/j.jtauto.2021.100127_bib43) 2011; 12 Livingstone (10.1016/j.jtauto.2021.100127_bib3) 2015; 313 DiMeglio (10.1016/j.jtauto.2021.100127_bib2) 2018; 391 Li (10.1016/j.jtauto.2021.100127_bib7) 2015; 21 Zhao (10.1016/j.jtauto.2021.100127_bib30) 2019; 203 Grieb (10.1016/j.jtauto.2021.100127_bib15) 2010; 23 Lonsdale (10.1016/j.jtauto.2021.100127_bib46) 2013; 45 Vergunst (10.1016/j.jtauto.2021.100127_bib50) 2008; 58 Norris (10.1016/j.jtauto.2021.100127_bib33) 2007; 298 Swerdlow (10.1016/j.jtauto.2021.100127_bib42) 2012; 379 Bose (10.1016/j.jtauto.2021.100127_bib23) 2013; 36 Folkersen (10.1016/j.jtauto.2021.100127_bib31) 2020; 2 Ismail (10.1016/j.jtauto.2021.100127_bib16) 2016; 29 Eisenbarth (10.1016/j.jtauto.2021.100127_bib1) 1986; 314 Onengut-Gumuscu (10.1016/j.jtauto.2021.100127_bib6) 2015; 47 Piemonti (10.1016/j.jtauto.2021.100127_bib19) 2002; 51 Cui (10.1016/j.jtauto.2021.100127_bib27) 2020; 83 Novakova (10.1016/j.jtauto.2021.100127_bib24) 2017; 141 Purohit (10.1016/j.jtauto.2021.100127_bib14) 2015; 100 Solomon (10.1016/j.jtauto.2021.100127_bib13) 2010; 43 Gilbert (10.1016/j.jtauto.2021.100127_bib28) 2011; 107 |
| References_xml | – volume: 314 start-page: 1360 year: 1986 end-page: 1368 ident: bib1 article-title: Type I diabetes mellitus. A chronic autoimmune disease publication-title: N. Engl. J. Med. – volume: 83 start-page: 106314 year: 2020 ident: bib27 article-title: The role of chemokines and chemokine receptors in multiple sclerosis publication-title: Int. Immunopharm. – volume: 12 start-page: 996 year: 2002 end-page: 1006 ident: bib9 article-title: The human genome browser at UCSC publication-title: Genome Res. – volume: 90 start-page: 772 year: 1992 end-page: 779 ident: bib21 article-title: Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis publication-title: J. Clin. Invest. – volume: 116 start-page: 115 year: 2006 end-page: 124 ident: bib38 article-title: CCR2 modulates inflammatory and metabolic effects of high-fat feeding publication-title: J. Clin. Invest. – volume: 2 start-page: 1135 year: 2020 end-page: 1148 ident: bib31 article-title: Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals publication-title: Nat Metab – volume: 12 start-page: 60 year: 2020 ident: bib40 article-title: Multi-method genome- and epigenome-wide studies of inflammatory protein levels in healthy older adults publication-title: Genome Med. – volume: 104 start-page: 88 year: 2001 end-page: 91 ident: bib25 article-title: Differential release of β‐chemokines in serum and CSF of patients with relapsing–remitting multiple sclerosis publication-title: Acta Neurol. Scand. – volume: 38 start-page: 963 year: 1982 end-page: 974 ident: bib35 article-title: Random-effects models for longitudinal data publication-title: Biometrics – volume: 12 start-page: 733 year: 2011 end-page: 743 ident: bib43 article-title: The Environmental Determinants of Diabetes in the Young (TEDDY): genetic criteria and international diabetes risk screening of 421 000 infants publication-title: Pediatr. Diabetes – volume: 198 start-page: 4659 year: 2017 end-page: 4671 ident: bib10 article-title: CCR2 regulates the immune response by modulating the interconversion and function of effector and regulatory T cells publication-title: J. Immunol. – volume: 43 start-page: 156 year: 2010 end-page: 163 ident: bib13 article-title: CCR2 and CCR5 chemokine receptors differentially influence the development of autoimmune diabetes in the NOD mouse publication-title: Autoimmunity – volume: 107 start-page: 906 year: 2011 end-page: 911 ident: bib28 article-title: Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region publication-title: Am. J. Cardiol. – volume: 8 start-page: 1031 year: 2020 ident: bib44 article-title: Immune transcriptome of cells infected with enterovirus strains obtained from cases of type 1 diabetes publication-title: Microorganisms – volume: 12 year: 2017 ident: bib17 article-title: Increased inflammation is associated with islet autoimmunity and type 1 diabetes in the Diabetes Autoimmunity Study in the Young (DAISY) publication-title: PLoS One – volume: 36 year: 2018 ident: bib48 article-title: Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: correlation with blood monocyte counts publication-title: J. Clin. Oncol. – volume: 51 start-page: 55 year: 2002 end-page: 65 ident: bib19 article-title: Human pancreatic islets produce and secrete MCP-1/CCL2: relevance in human islet transplantation publication-title: Diabetes – volume: 26 start-page: 2336 year: 2010 end-page: 2337 ident: bib37 article-title: LocusZoom: regional visualization of genome-wide association scan results publication-title: Bioinformatics – volume: 394 start-page: 1286 year: 2019 end-page: 1296 ident: bib52 article-title: Changing the landscape for type 1 diabetes: the first step to prevention publication-title: Lancet – year: 1998 ident: bib34 article-title: Applied Regression Analysis – volume: 41 start-page: 703 year: 2009 end-page: 707 ident: bib5 article-title: Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes publication-title: Nat. Genet. – volume: 21 start-page: 1018 year: 2015 end-page: 1027 ident: bib7 article-title: Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases publication-title: Nat. Med. – volume: 7 start-page: 421 year: 2017 ident: bib12 article-title: Enhancement of CCL2 expression and monocyte migration by CCN1 in osteoblasts through inhibiting miR-518a-5p: implication of rheumatoid arthritis therapy publication-title: Sci. Rep. – volume: 13 year: 2011 ident: bib45 article-title: Promise and pitfalls of the Immunochip publication-title: Arthritis Res. Ther. – volume: 107 start-page: 906 year: 2011 end-page: 911 ident: bib51 article-title: Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region publication-title: Am. J. Cardiol. – volume: 3 start-page: 1316 year: 2018 end-page: 1327 ident: bib49 article-title: Effect of PF-04634817, an oral CCR2/5 chemokine receptor antagonist, on albuminuria in adults with overt diabetic nephropathy publication-title: Kidney international reports – volume: 117 start-page: 1129 year: 2020 end-page: 1138 ident: bib47 article-title: CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas publication-title: Proc. Natl. Acad. Sci. Unit. States Am. – volume: 13 start-page: 670 year: 2001 end-page: 675 ident: bib8 article-title: Chemokines in autoimmune disease publication-title: Curr. Opin. Immunol. – volume: 6 start-page: 32 year: 2009 ident: bib29 article-title: CCR2 and CXCR4 regulate peripheral blood monocyte pharmacodynamics and link to efficacy in experimental autoimmune encephalomyelitis publication-title: J. Inflamm. – volume: 39 start-page: 807 year: 1996 end-page: 812 ident: bib32 article-title: Newborn screening for HLA markers associated with IDDM: diabetes autoimmunity study in the young (DAISY) publication-title: Diabetologia – volume: 100 start-page: E1179 year: 2015 end-page: E1187 ident: bib14 article-title: Large-scale discovery and validation studies demonstrate significant reductions in circulating levels of IL8, IL-1Ra, MCP-1, and MIP-1β in patients with type 1 diabetes publication-title: J. Clin. Endocrinol. Metabol. – volume: 29 start-page: 641 year: 2016 end-page: 645 ident: bib16 article-title: Monocyte chemoattractant protein 1 and macrophage migration inhibitory factor in children with type 1 diabetes publication-title: J. Pediatr. Endocrinol. Metab. – volume: 203 start-page: 3157 year: 2019 end-page: 3165 ident: bib30 article-title: CCR2-Mediated uptake of constitutively produced CCL2: a mechanism for regulating chemokine levels in the blood publication-title: J. Immunol. – volume: 60 start-page: 1 year: 2012 end-page: 12 ident: bib18 article-title: Monocyte chemoattractant protein 1 (MCP-1) in obesity and diabetes publication-title: Cytokine – volume: 47 start-page: D1005 year: 2019 end-page: d1012 ident: bib39 article-title: The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019 publication-title: Nucleic Acids Res. – volume: 23 start-page: 257 year: 2010 ident: bib15 article-title: Macrophage migration inhibitory factor (MIF): a promising biomarker publication-title: Drug News Perspect. – volume: 83 start-page: 672 year: 2005 end-page: 681 ident: bib20 article-title: The complex role of the chemokine receptor CCR2 in collagen-induced arthritis: implications for therapeutic targeting of CCR2 in rheumatoid arthritis publication-title: J. Mol. Med. (Berl.) – volume: 81 start-page: 559 year: 2007 end-page: 575 ident: bib36 article-title: PLINK: a tool set for whole-genome association and population-based linkage analyses publication-title: Am. J. Hum. Genet. – volume: 298 start-page: 1420 year: 2007 end-page: 1428 ident: bib33 article-title: Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at increased risk for type 1 diabetes publication-title: Jama – volume: 381 start-page: 603 year: 2019 end-page: 613 ident: bib4 article-title: An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes publication-title: N. Engl. J. Med. – volume: 58 start-page: 1931 year: 2008 end-page: 1939 ident: bib26 article-title: Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial publication-title: Arthritis Rheum. – volume: 36 start-page: 1039 year: 2013 end-page: 1050 ident: bib23 article-title: J. Role of chemokine CCL2 and its receptor CCR2 in neurodegenerative diseases publication-title: Arch Pharm. Res. (Seoul) – volume: 391 start-page: 2449 year: 2018 end-page: 2462 ident: bib2 article-title: Type 1 diabetes publication-title: Lancet – volume: 58 start-page: 1931 year: 2008 end-page: 1939 ident: bib50 article-title: Modulation of CCR2 in rheumatoid arthritis: a double‐blind, randomized, placebo‐controlled clinical trial publication-title: Arthritis Rheum.: Official Journal of the American College of Rheumatology – volume: 11 start-page: 23 year: 2014 ident: bib11 article-title: Macrophages migrate in an activation-dependent manner to chemokines involved in neuroinflammation publication-title: J. Neuroinflammation – volume: 45 start-page: 580 year: 2013 end-page: 585 ident: bib46 article-title: The genotype-tissue expression (GTEx) project publication-title: Nat. Genet. – volume: 379 start-page: 1214 year: 2012 end-page: 1224 ident: bib42 article-title: The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis publication-title: Lancet – volume: 65 start-page: 294 year: 2006 end-page: 300 ident: bib22 article-title: Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis publication-title: Ann. Rheum. Dis. – volume: 47 start-page: 381 year: 2015 end-page: 386 ident: bib6 article-title: Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers publication-title: Nat. Genet. – volume: 141 start-page: 296 year: 2017 end-page: 304 ident: bib24 article-title: Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing‐remitting multiple sclerosis publication-title: J. Neurochem. – volume: 379 start-page: 1205 year: 2012 end-page: 1213 ident: bib41 article-title: IL6R Genetics Consortium Emerging Risk Factors Collaboration: interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies publication-title: Lancet – volume: 313 start-page: 37 year: 2015 end-page: 44 ident: bib3 article-title: Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010 publication-title: Jama – volume: 39 start-page: 807 year: 1996 ident: 10.1016/j.jtauto.2021.100127_bib32 article-title: Newborn screening for HLA markers associated with IDDM: diabetes autoimmunity study in the young (DAISY) publication-title: Diabetologia doi: 10.1007/s001250050514 – volume: 47 start-page: D1005 year: 2019 ident: 10.1016/j.jtauto.2021.100127_bib39 article-title: The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019 publication-title: Nucleic Acids Res. doi: 10.1093/nar/gky1120 – volume: 198 start-page: 4659 year: 2017 ident: 10.1016/j.jtauto.2021.100127_bib10 article-title: CCR2 regulates the immune response by modulating the interconversion and function of effector and regulatory T cells publication-title: J. Immunol. doi: 10.4049/jimmunol.1601458 – volume: 391 start-page: 2449 year: 2018 ident: 10.1016/j.jtauto.2021.100127_bib2 article-title: Type 1 diabetes publication-title: Lancet doi: 10.1016/S0140-6736(18)31320-5 – volume: 314 start-page: 1360 year: 1986 ident: 10.1016/j.jtauto.2021.100127_bib1 article-title: Type I diabetes mellitus. A chronic autoimmune disease publication-title: N. Engl. J. Med. doi: 10.1056/NEJM198605223142106 – volume: 81 start-page: 559 year: 2007 ident: 10.1016/j.jtauto.2021.100127_bib36 article-title: PLINK: a tool set for whole-genome association and population-based linkage analyses publication-title: Am. J. Hum. Genet. doi: 10.1086/519795 – volume: 13 year: 2011 ident: 10.1016/j.jtauto.2021.100127_bib45 article-title: Promise and pitfalls of the Immunochip publication-title: Arthritis Res. Ther. – volume: 100 start-page: E1179 year: 2015 ident: 10.1016/j.jtauto.2021.100127_bib14 article-title: Large-scale discovery and validation studies demonstrate significant reductions in circulating levels of IL8, IL-1Ra, MCP-1, and MIP-1β in patients with type 1 diabetes publication-title: J. Clin. Endocrinol. Metabol. doi: 10.1210/JC.2015-1388 – volume: 36 year: 2018 ident: 10.1016/j.jtauto.2021.100127_bib48 article-title: Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: correlation with blood monocyte counts publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2018.36.5_suppl.92 – volume: 2 start-page: 1135 year: 2020 ident: 10.1016/j.jtauto.2021.100127_bib31 article-title: Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals publication-title: Nat Metab doi: 10.1038/s42255-020-00287-2 – year: 1998 ident: 10.1016/j.jtauto.2021.100127_bib34 – volume: 117 start-page: 1129 year: 2020 ident: 10.1016/j.jtauto.2021.100127_bib47 article-title: CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas publication-title: Proc. Natl. Acad. Sci. Unit. States Am. doi: 10.1073/pnas.1910856117 – volume: 90 start-page: 772 year: 1992 ident: 10.1016/j.jtauto.2021.100127_bib21 article-title: Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis publication-title: J. Clin. Invest. doi: 10.1172/JCI115950 – volume: 43 start-page: 156 year: 2010 ident: 10.1016/j.jtauto.2021.100127_bib13 article-title: CCR2 and CCR5 chemokine receptors differentially influence the development of autoimmune diabetes in the NOD mouse publication-title: Autoimmunity doi: 10.3109/08916930903246464 – volume: 41 start-page: 703 year: 2009 ident: 10.1016/j.jtauto.2021.100127_bib5 article-title: Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes publication-title: Nat. Genet. doi: 10.1038/ng.381 – volume: 23 start-page: 257 year: 2010 ident: 10.1016/j.jtauto.2021.100127_bib15 article-title: Macrophage migration inhibitory factor (MIF): a promising biomarker publication-title: Drug News Perspect. doi: 10.1358/dnp.2010.23.4.1453629 – volume: 141 start-page: 296 year: 2017 ident: 10.1016/j.jtauto.2021.100127_bib24 article-title: Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing‐remitting multiple sclerosis publication-title: J. Neurochem. doi: 10.1111/jnc.13881 – volume: 26 start-page: 2336 year: 2010 ident: 10.1016/j.jtauto.2021.100127_bib37 article-title: LocusZoom: regional visualization of genome-wide association scan results publication-title: Bioinformatics doi: 10.1093/bioinformatics/btq419 – volume: 36 start-page: 1039 year: 2013 ident: 10.1016/j.jtauto.2021.100127_bib23 article-title: J. Role of chemokine CCL2 and its receptor CCR2 in neurodegenerative diseases publication-title: Arch Pharm. Res. (Seoul) doi: 10.1007/s12272-013-0161-z – volume: 3 start-page: 1316 year: 2018 ident: 10.1016/j.jtauto.2021.100127_bib49 article-title: Effect of PF-04634817, an oral CCR2/5 chemokine receptor antagonist, on albuminuria in adults with overt diabetic nephropathy publication-title: Kidney international reports doi: 10.1016/j.ekir.2018.07.010 – volume: 83 start-page: 106314 year: 2020 ident: 10.1016/j.jtauto.2021.100127_bib27 article-title: The role of chemokines and chemokine receptors in multiple sclerosis publication-title: Int. Immunopharm. doi: 10.1016/j.intimp.2020.106314 – volume: 45 start-page: 580 year: 2013 ident: 10.1016/j.jtauto.2021.100127_bib46 article-title: The genotype-tissue expression (GTEx) project publication-title: Nat. Genet. doi: 10.1038/ng.2653 – volume: 12 start-page: 733 year: 2011 ident: 10.1016/j.jtauto.2021.100127_bib43 article-title: The Environmental Determinants of Diabetes in the Young (TEDDY): genetic criteria and international diabetes risk screening of 421 000 infants publication-title: Pediatr. Diabetes doi: 10.1111/j.1399-5448.2011.00774.x – volume: 107 start-page: 906 year: 2011 ident: 10.1016/j.jtauto.2021.100127_bib51 article-title: Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region publication-title: Am. J. Cardiol. doi: 10.1016/j.amjcard.2010.11.005 – volume: 6 start-page: 32 year: 2009 ident: 10.1016/j.jtauto.2021.100127_bib29 article-title: CCR2 and CXCR4 regulate peripheral blood monocyte pharmacodynamics and link to efficacy in experimental autoimmune encephalomyelitis publication-title: J. Inflamm. doi: 10.1186/1476-9255-6-32 – volume: 107 start-page: 906 year: 2011 ident: 10.1016/j.jtauto.2021.100127_bib28 article-title: Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region publication-title: Am. J. Cardiol. doi: 10.1016/j.amjcard.2010.11.005 – volume: 298 start-page: 1420 year: 2007 ident: 10.1016/j.jtauto.2021.100127_bib33 article-title: Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at increased risk for type 1 diabetes publication-title: Jama doi: 10.1001/jama.298.12.1420 – volume: 379 start-page: 1214 year: 2012 ident: 10.1016/j.jtauto.2021.100127_bib42 article-title: The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis publication-title: Lancet doi: 10.1016/S0140-6736(12)60110-X – volume: 21 start-page: 1018 year: 2015 ident: 10.1016/j.jtauto.2021.100127_bib7 article-title: Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases publication-title: Nat. Med. doi: 10.1038/nm.3933 – volume: 38 start-page: 963 year: 1982 ident: 10.1016/j.jtauto.2021.100127_bib35 article-title: Random-effects models for longitudinal data publication-title: Biometrics doi: 10.2307/2529876 – volume: 51 start-page: 55 year: 2002 ident: 10.1016/j.jtauto.2021.100127_bib19 article-title: Human pancreatic islets produce and secrete MCP-1/CCL2: relevance in human islet transplantation publication-title: Diabetes doi: 10.2337/diabetes.51.1.55 – volume: 58 start-page: 1931 year: 2008 ident: 10.1016/j.jtauto.2021.100127_bib50 article-title: Modulation of CCR2 in rheumatoid arthritis: a double‐blind, randomized, placebo‐controlled clinical trial publication-title: Arthritis Rheum.: Official Journal of the American College of Rheumatology doi: 10.1002/art.23591 – volume: 8 start-page: 1031 year: 2020 ident: 10.1016/j.jtauto.2021.100127_bib44 article-title: Immune transcriptome of cells infected with enterovirus strains obtained from cases of type 1 diabetes publication-title: Microorganisms doi: 10.3390/microorganisms8071031 – volume: 12 year: 2017 ident: 10.1016/j.jtauto.2021.100127_bib17 article-title: Increased inflammation is associated with islet autoimmunity and type 1 diabetes in the Diabetes Autoimmunity Study in the Young (DAISY) publication-title: PLoS One doi: 10.1371/journal.pone.0174840 – volume: 379 start-page: 1205 year: 2012 ident: 10.1016/j.jtauto.2021.100127_bib41 article-title: IL6R Genetics Consortium Emerging Risk Factors Collaboration: interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies publication-title: Lancet doi: 10.1016/S0140-6736(11)61931-4 – volume: 29 start-page: 641 year: 2016 ident: 10.1016/j.jtauto.2021.100127_bib16 article-title: Monocyte chemoattractant protein 1 and macrophage migration inhibitory factor in children with type 1 diabetes publication-title: J. Pediatr. Endocrinol. Metab. doi: 10.1515/jpem-2015-0340 – volume: 58 start-page: 1931 year: 2008 ident: 10.1016/j.jtauto.2021.100127_bib26 article-title: Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial publication-title: Arthritis Rheum. doi: 10.1002/art.23591 – volume: 65 start-page: 294 year: 2006 ident: 10.1016/j.jtauto.2021.100127_bib22 article-title: Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis publication-title: Ann. Rheum. Dis. doi: 10.1136/ard.2005.037176 – volume: 116 start-page: 115 year: 2006 ident: 10.1016/j.jtauto.2021.100127_bib38 article-title: CCR2 modulates inflammatory and metabolic effects of high-fat feeding publication-title: J. Clin. Invest. doi: 10.1172/JCI24335 – volume: 12 start-page: 996 year: 2002 ident: 10.1016/j.jtauto.2021.100127_bib9 article-title: The human genome browser at UCSC publication-title: Genome Res. doi: 10.1101/gr.229102 – volume: 47 start-page: 381 year: 2015 ident: 10.1016/j.jtauto.2021.100127_bib6 article-title: Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers publication-title: Nat. Genet. doi: 10.1038/ng.3245 – volume: 12 start-page: 60 year: 2020 ident: 10.1016/j.jtauto.2021.100127_bib40 article-title: Multi-method genome- and epigenome-wide studies of inflammatory protein levels in healthy older adults publication-title: Genome Med. doi: 10.1186/s13073-020-00754-1 – volume: 104 start-page: 88 year: 2001 ident: 10.1016/j.jtauto.2021.100127_bib25 article-title: Differential release of β‐chemokines in serum and CSF of patients with relapsing–remitting multiple sclerosis publication-title: Acta Neurol. Scand. doi: 10.1034/j.1600-0404.2001.104002088.x – volume: 381 start-page: 603 year: 2019 ident: 10.1016/j.jtauto.2021.100127_bib4 article-title: An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1902226 – volume: 11 start-page: 23 year: 2014 ident: 10.1016/j.jtauto.2021.100127_bib11 article-title: Macrophages migrate in an activation-dependent manner to chemokines involved in neuroinflammation publication-title: J. Neuroinflammation doi: 10.1186/1742-2094-11-23 – volume: 313 start-page: 37 year: 2015 ident: 10.1016/j.jtauto.2021.100127_bib3 article-title: Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010 publication-title: Jama doi: 10.1001/jama.2014.16425 – volume: 60 start-page: 1 year: 2012 ident: 10.1016/j.jtauto.2021.100127_bib18 article-title: Monocyte chemoattractant protein 1 (MCP-1) in obesity and diabetes publication-title: Cytokine doi: 10.1016/j.cyto.2012.06.018 – volume: 203 start-page: 3157 year: 2019 ident: 10.1016/j.jtauto.2021.100127_bib30 article-title: CCR2-Mediated uptake of constitutively produced CCL2: a mechanism for regulating chemokine levels in the blood publication-title: J. Immunol. doi: 10.4049/jimmunol.1900961 – volume: 394 start-page: 1286 year: 2019 ident: 10.1016/j.jtauto.2021.100127_bib52 article-title: Changing the landscape for type 1 diabetes: the first step to prevention publication-title: Lancet doi: 10.1016/S0140-6736(19)32127-0 – volume: 7 start-page: 421 year: 2017 ident: 10.1016/j.jtauto.2021.100127_bib12 article-title: Enhancement of CCL2 expression and monocyte migration by CCN1 in osteoblasts through inhibiting miR-518a-5p: implication of rheumatoid arthritis therapy publication-title: Sci. Rep. doi: 10.1038/s41598-017-00513-0 – volume: 83 start-page: 672 year: 2005 ident: 10.1016/j.jtauto.2021.100127_bib20 article-title: The complex role of the chemokine receptor CCR2 in collagen-induced arthritis: implications for therapeutic targeting of CCR2 in rheumatoid arthritis publication-title: J. Mol. Med. (Berl.) doi: 10.1007/s00109-005-0637-5 – volume: 13 start-page: 670 year: 2001 ident: 10.1016/j.jtauto.2021.100127_bib8 article-title: Chemokines in autoimmune disease publication-title: Curr. Opin. Immunol. doi: 10.1016/S0952-7915(01)00277-1 |
| SSID | ssj0002511162 |
| Score | 2.1532712 |
| Snippet | Multiple cross-sectional and longitudinal studies have shown that serum levels of the chemokine ligand 2 (CCL-2) are associated with type 1 diabetes (T1D),... |
| SourceID | doaj pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 100127 |
| SubjectTerms | Autoimmune CCL2 CCR2 DAISY Fine mapping MCP1 Research paper T1D |
| Title | The 3p21.31 genetic locus promotes progression to type 1 diabetes through the CCR2/CCL2 pathway |
| URI | https://dx.doi.org/10.1016/j.jtauto.2021.100127 https://www.ncbi.nlm.nih.gov/pubmed/35005592 https://www.proquest.com/docview/2618514826 https://pubmed.ncbi.nlm.nih.gov/PMC8716652 https://doaj.org/article/1519344225d94ba5ba649cd300bb4141 |
| Volume | 4 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlUOilNOlrmyao0KuJrYclHVvTEELbQ2kgN6GX24TiXRovJf--M5K97DaHvfS0Zte7Wmk-e74Zj-Yj5L1RDWu1VxVLKGFW81T5VrvKeCnaCDcH4TDf8eVre3ElLq_l9ZbUF9aElfbAZeHOGqQYQgDsohHeSe9aYULkde29aPKWdQY-byuYwnswEucmq4kyqU1lalPP--Zycdft6NYj7v1jTe5ChKIyW34pt-_fcU8P6ee_VZRbbun8GXk68Un6oczjkDxKwxF5XBQm758TCzCgfAXj84YCVnDLIgX_tb6jq1yIl_LBj1INO9BxSTEpSxs6J2XppOQDr4l23Td21nWfGUUl4z_u_gW5Ov_0vbuoJk2FKkhmxkpKLzmEcD6HpzqZ6IAg9m3NNayrizrKxFWAKKbvnZbROxZCjCJoHaJKkr8kB8NySK8JBW6jo2ZJKSBdoVc-KMeZTqpvda3auCB8XlEbpobjqHvxy86VZbe22MGiHWyxw4JUm2-tSsONPed_RGNtzsV22fkNAJGdQGT3gWhB1GxqOzGPwijgp272DP9uRoaFCxOftrghLdd3FkJTYLMCwrcFeVWQsvmTXGLvM8Ng3B0M7cxi95Ph5mdu_o0BbivZm_8x7WPyBKdSMkpvycH4e51OgGON_jRfTqc5-fUXau0giw |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+3p21.31+genetic+locus+promotes+progression+to+type+1+diabetes+through+the+CCR2%2FCCL2+pathway&rft.jtitle=Journal+of+translational+autoimmunity+%28Online%29&rft.au=Paul+MH.+Tran&rft.au=Sharad+Purohit&rft.au=Eileen+Kim&rft.au=Khaled+bin+Satter&rft.date=2021-01-01&rft.pub=Elsevier&rft.issn=2589-9090&rft.eissn=2589-9090&rft.volume=4&rft.spage=100127&rft_id=info:doi/10.1016%2Fj.jtauto.2021.100127&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_1519344225d94ba5ba649cd300bb4141 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2589-9090&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2589-9090&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2589-9090&client=summon |